Saturday 17 October 2026
Export TECX’s income statement to Excel — free account
Tectonic Therapeutic, Inc.
TECX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 10.3%, free cash flow fell 46.7% and total debt fell 94.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
20.65
0.65
−3.05%
Follow TECX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
22.29 | 18.51 | 26.63 | 29.15 |
+8 more quarters Free account |
Net Debt/EBITDA |
9.49 | 8.77 | 12.01 | 12.48 | |
Debt/Assets |
0.00% | 0.01% | 0.02% | 0.04% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.96 | 0.73 | 0.75 | 0.94 | |
Capex/Depreciation |
(0.21) | (0.06) | 0.00 | (0.49) | |
Interest Coverage |
(4,036.33) | (3,412.62) | (1,793.00) | (1,563.57) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.13) | (0.98) | (0.79) | (0.96) | |
Cash per Share |
11.97 | 12.62 | 13.88 | 14.38 | |
Shareholders Equity per Share |
11.80 | 12.28 | 13.72 | 14.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.80 | 12.28 | 13.72 | 14.30 | |
Free Cash Flow |
(21.51) | (18.43) | (14.46) | (17.98) | |
Working Capital |
220.73 | 226.93 | 247.69 | 263.87 | |
Capital Expenditures |
(0.06) | (0.02) | 0.00 | (0.17) | |
Net Current Asset Value |
217.91 | 223.73 | 247.65 | 263.77 | |
| Other line items | |||||
Quick Ratio |
21.90 | 18.28 | 26.32 | 28.70 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.13) | (0.98) | (0.79) | (0.95) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Average Payables |
2.24 | 4.40 | 1.03 | 2.06 | |
Average Assets |
266.17 | 280.70 | 206.97 | 222.86 | |
Average Common Equity |
253.81 | 265.73 | 196.05 | 208.94 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates